(HHS, 2022) Its recommended that healthy adults engage in at least 150 minutes of moderate-intensity aerobic activity per week, such as brisk walking or cycling
Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents the newest class of weight loss medications with remarkable clinical trial results from the SURMOUNT studies (Jastreboff et al., NEJM, 2022)
Orforglipron Name: Orforglipron Manufacturer: Eli Lilly Current stage: Expected to submit for regulatory approval by the end of 2025 Takeaway: Less effective than injectables for mean weight loss, but a daily pill could suit some patients better
Injection Technique General subcutaneous guidance from clinical best-practice resources [8] [10] [11]
doi: 10.1016/j.cmet.2013.03.002 149 KlugeMAFettermanJLVitaJA
Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol